Rare
lephants
Screener
Toggle theme
C
C21 Investments Inc.
CWLXF
·
Healthcare, Drug Manufacturers - General
Financial Statements
Profitability
Balance Sheet
Cash Flow
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2026
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Total Cash from Operations:
$2.6M
Line Item
Value
% of Total
Capital Expenditures
$406.7K
15.9%
Stock Repurchases
$276.7K
10.8%
Working Capital
$1.2M
46.6%
Other
$682.2K
26.7%
Net Cash Flow
$0
0.0%
Download CSV